thiazoles has been researched along with sdz psc 833 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Ando, Y; Bates, SE; Blagosklonny, MV; Figg, WD; Fojo, T; Kang, MH; Liewehr, D | 1 |
| Blagosklonny, MV | 1 |
| Kurttila, T; Myllynen, P; Vähäkangas, K; Vaskivuo, L | 1 |
| Apáti, A; Hegedus, C; Katona, M; Kéri, G; Magócsi, M; Német, K; Orfi, L; Ozvegy-Laczka, C; Sarkadi, B; Szakács, G; Takáts, Z; Váradi, A | 1 |
1 trial(s) available for thiazoles and sdz psc 833
| Article | Year |
|---|---|
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bilirubin; Chromatography, High Pressure Liquid; Coloring Agents; Cyclosporins; Dose-Response Relationship, Drug; HL-60 Cells; Humans; Inhibitory Concentration 50; K562 Cells; Microsomes, Liver; Models, Chemical; Paclitaxel; Taxoids; Tetrazolium Salts; Thiazoles; Time Factors | 2001 |
4 other study(ies) available for thiazoles and sdz psc 833
| Article | Year |
|---|---|
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Cyclosporins; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA Fragmentation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Epoxy Compounds; Flavonoids; Hematopoietic Stem Cells; HL-60 Cells; Humans; Jurkat Cells; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oligopeptides; Paclitaxel; Piperidines; Poly(ADP-ribose) Polymerases; Pyrazines; Substrate Specificity; Thiazoles | 2001 |
DNA damage caused by benzo(a)pyrene in MCF-7 cells is increased by verapamil, probenecid and PSC833.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzo(a)pyrene; Calcium Channel Blockers; Carcinogens; Cell Line, Tumor; Cell Survival; Cyclosporins; DNA Adducts; DNA Damage; Drug Synergism; Female; Humans; Probenecid; Renal Agents; Tetrazolium Salts; Thiazoles; Tumor Suppressor Protein p53; Verapamil | 2007 |
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Topics: Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cyclosporins; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Fusion Proteins, bcr-abl; Humans; Indoles; K562 Cells; Neoplasm Proteins; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Substrate Specificity; Thiazoles | 2009 |